Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Progestogen-only contraception

Essential points for quick revision.

Saved on this device
!
Recent missed use can create pregnancy risk

A late pill plus recent unprotected intercourse may require emergency contraception before routine continuation advice.

Action: Identify the exact POP formulation and elapsed time since the previous pill, assess copper IUD and oral EC eligibility, restart correctly, specify backup duration and arrange a pregnancy test 21 days after the latest risk.

Synopsis

Distinguish traditional, desogestrel and drospirenone pills, apply exact late and missed-use rules, and manage interactions, bleeding and safe initiation without oestrogen.

  • Traditional levonorgestrel or norethisterone POP has a three-hour late window, desogestrel has a 12-hour window and drospirenone has a 24-hour window; missed use begins beyond 27, 36 and 48 hours since the previous pill respectively.
  • Take the missed pill as soon as remembered and continue at the usual time, even if two are taken in one day; use backup for 48 hours with traditional or desogestrel POP and seven days with drospirenone POP.
  • Assess EC after unprotected sex from the time the first pill was missed until efficacy is re-established. Recent progestogen can reduce UPA effect, so use the current EC algorithm.

Key red flags

A traditional POP is missed when more than 27 hours have elapsed since the last pill, desogestrel after more than 36 hours and drospirenone after more than 48 hours; the windows are not interchangeable.

After missed traditional or desogestrel POP, use condoms or abstain until 48 hours of correct use; after missed drospirenone POP, use additional precautions for seven days.

Enzyme inducers reduce every oral POP during use and for 28 days after stopping; DMPA, LNG-IUD and copper IUD effectiveness is unaffected.

New severe unilateral pain, collapse or bleeding with pregnancy possibility requires urgent ectopic-pregnancy assessment.

Drospirenone has antimineralocorticoid activity, so renal disease, adrenal insufficiency and interacting potassium-raising medicines require product-specific review.

Traditional POP error

More than 27 hours since the previous levonorgestrel or norethisterone pill is missed use and triggers 48-hour backup.

Desogestrel POP error

More than 36 hours since the previous desogestrel pill exceeds its 12-hour allowance and needs 48-hour backup.

Drospirenone active-pill error

More than 48 hours since the previous active drospirenone pill exceeds its 24-hour window and requires seven-day backup.

Possible ectopic pregnancy

Pain, bleeding or collapse with a positive or possible pregnancy requires urgent pregnancy-location assessment despite low absolute risk.

Investigation priorities

01
Exact product and dosing historyFirst step

Determine the active ingredient, pack design and elapsed time since the last active tablet.

Management branches

Missed-pill pathwayName the pill before counting hours

A POP user reports a pill later than the scheduled time.

  1. Confirm traditional, desogestrel or drospirenone formulation and calculate hours since the previous active tablet.
  2. Apply the 27-, 36- or 48-hour threshold, take an active pill now and continue the pack.

Key medicines

Desogestrel 75 microgram POPTake one active tablet orally at the same time every day without a hormone-free interval; a dose is late after 12 hours and missed after more than 36 hours since the prior pill.After missed use take a pill now, continue daily, use 48-hour backup and assess EC; enzyme inducers reduce effectiveness.
Drospirenone 4mg POPTake one active tablet daily for 24 days followed by four placebo tablets; an active pill is late after 24 hours and missed beyond 48 hours since the previous active pill.Use seven days of backup after relevant missed active pills; review renal, hepatic or adrenal disease and potassium-raising interactions.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom